The development of nanocarriers to prolong the residence
time and
enhance the permeability of chemotherapeutic drugs on bladder mucosa
is important in the postsurgery treatment of superficial bladder cancers
(BCs). Here, the mucoadhesive HA-SH/PF127 nanogels composed of a temperature-sensitive
Pluronic F127 (PF127) core and thiolated hyaluronic acid (HA-SH) shell
were prepared by the emulsification/solvent evaporation method. The
nanogels were constructed through the thiol-maleimide click reaction
in the HA-SH aqueous side of the oil–water interface and self-oxidized
cross-linking thiols between HA-SH. The HA-SH/PF127 nanogels prepared
at different thiol-to-maleimide group molar ratios, water-to-oil volume
ratios, and cross-linking reaction times were characterized regarding
hydrodynamic diameter (Dh) and zeta potential
(ζ), and the optimal formulation was obtained. The excellent
mucoadhesive properties of the HA-SH/PF127 nanogels were evaluated
by using the mucin particle method. Doxorubicin (DOX) was encapsulated
in the PF127 core of DOX@HA-SH/PF127 nanogels with a high loading
efficiency (87.5%) and sustained release from the nanogels in artificial
urine. Ex vivo studies on porcine bladder mucosa
showed that the DOX@HA-SH/PF127 nanogels enhanced the penetration
of the DOX into the bladder mucosa without disrupting the mucus structure
or the bladder tissue. A significant dose-dependent cytotoxic effect
of DOX@HA-SH/PF127 nanogels on both T24 and MB49 cells was observed.
The present study demonstrates that the mucoadhesive HA-SH/PF127 nanogels
are a promising intravesical drug delivery system for superficial
BC therapy.